Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chimpanzee adenovirus-vectored SARS-CoV-2 vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Third People's Hospital
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The chimpanzee adenovirus-vectored SARS-CoV-2 vaccine is a viral vector vaccine platform that utilizes a non-replicating chimpanzee adenovirus (ChAd) to deliver the genetic sequence of the SARS-CoV-2 spike protein. This approach is designed to circumvent pre-existing immunity to human adenoviruses (such as Ad5), which can limit vaccine efficacy. A specific candidate using this platform, often referred to as AdC68-nCoV or AdC68-S, was developed by the Third People's Hospital of Shenzhen in collaboration with Tsinghua University. It has been investigated in clinical trials (e.g., ChiCTR2100053473) as a heterologous booster dose to enhance immune responses in individuals who previously received inactivated COVID-19 vaccines. The vaccine aims to induce robust neutralizing antibody titers and T-cell responses against the SARS-CoV-2 virus.
- Other names
- ChAd-SARS-CoV-2ChAd-SARS-CoV2ChAd-SARS-CoV 2ChAd-SSARS-CoV-2 vaccine (chimpanzee adenovirus vector)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on chimpanzee adenovirus-vectored SARS-CoV-2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chimpanzee adenovirus-vectored SARS-CoV-2 vaccine.